ResearchPoint Global names José Iglesias as oncology director

Parachute
Iglesias had served as senior VP and CMO at Abraxis, and was named VP for clinical development at Celgene after Abraxis was acquired in 2010. He stayed on to guide Abraxane’s phase 3 development in breast and pancreatic cancers. (Pixabay)

ResearchPoint Global has brought on José Iglesias, M.D., as medical director for oncology to help develop the contract research organization’s strategy for cancer-focused sponsors.

Iglesias has previously held chief medical officer and senior development positions at Biothera, Bionomics, Celgene, Abraxis BioScience, Amgen Canada and Eli Lilly. Most recently, he was VP of medical and clinical affairs at Apobiologix, where he worked on the development of biosimilar cancer treatments.

“I have known José for over twenty years, and he is a very gifted scientist,” said Alfonso Alanis, M.D., chief medical officer of Austin, Texas-based ResearchPoint, which was acquired by WuXi AppTec last October, in a statement. “José is well known and well respected in the field of clinical oncology globally and has a broad network which includes some of the principal thought leaders in modern oncology. He has worked with some of the most traditional oncology platforms as well as the most novel ones including immuno-oncology and genomics.”

Your Daily Newsletter — Free

Enjoying this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. To read on the go, sign up today to get biotech news and updates delivered right to your inbox!

Over 28 years in the field, Iglesias has designed and led all phases of oncology clinical trials, and worked on more than 60 publications, ResearchPoint said in the statement. At Abraxis, Iglesias served as senior VP for global clinical development as well as CMO, and helped guide worldwide clinical development of Abraxane. After Celgene acquired Abraxis in 2010, he stayed on as VP for clinical development at Celgene, responsible for Abraxane’s phase 3 development in pancreatic cancer and metastatic breast cancer.

RELATED: WuXi AppTec continues worldwide expansion with ResearchPoint Global buy

Before that, Iglesias spent a decade at Eli Lilly in several positions, including associate director of clinical research and later medical adviser for oncology for Lilly’s Australian and Asian operations.